OncoSec Medical Inc (ONCSQ)

[lasers]

$ONCS Merkel Cell Cancer Clinical Trial Primary Completion Date: June 2015


Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer


https://clinicaltrials.gov/ct2/show/NCT01440816?term=OncoSec&rank=4

Estimated Enrollment: 15
Study Start Date: November 2011
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)

Merkel Cell Cancer is an Orphan Disease Designation so that any effecteive treatment would be given priority approval by the FDA and world wide regulatory agencies such as the UK MHRA and Europe EMA